Latest News



May 12, 2017 0

Specialty Drug Marketers Can Tap into Patient Stories

Stories are ingrained in us from the time we are infants. The nighttime ritual of parents and children cozying up with a storybook or two is a genuine and enjoyable encounter, one with an underlying message or lesson that is served in a palatable way. Once we begin reading for ourselves, we turn to stories to bring clarity to a topic, brighten an experience, or learn something new.

Patients often have many stories of their own to tell, no book needed. At each story’s core are kernels of information that can help biopharmaceutical marketers, healthcare professionals, and other patients understand an individual’s challenges and triumphs as well as reveal unmet needs and gaps in care.

What can be learned from the tale of an active female patient with rheumatoid arthritis? As it turns out, quite a lot. The story of Lisa Hehn’s journey includes a lot of twists and turns, revelations, and teaching moments relevant to brand marketers. Patient stories resonate. They illustrate real-life experiences, pull at heartstrings, and humanize disease.

Lisa’s Journey

Six months after her second child was born by cesarean section, Lisa woke up with total body pain. As a young mother, she needed to be well in order to care for her children and keep up with the daily demands of an active lifestyle that included walking, dance classes, and regular gym visits.

Lisa set out on an odyssey to discover the root cause of her pain and find a solution, relying primarily on library research and the expertise of numerous physicians and other healthcare professionals. Her pain was managed with anti-inflammatories, steroids, and other medications that left her with serious side effects including stomach bleeds. She wore wrist braces to carry her children, and even added carpet padding to her slippers to soften the pain of each step she took.

Years passed before a specialist diagnosed Lisa with rheumatoid arthritis and ultimately prescribed a TNF inhibitor to manage her disease. The change for Lisa was life-altering, in fact, she’s said that the biologic gave her life.

Drugstore Aisle Opportunities for Specialty Brands

Patient narratives like Lisa’s can help specialty brand marketers pinpoint effective marketing strategies across various channels at every step of the journey. Although Lisa’s disease is now well managed, that was not always the case. Prior to her diagnosis, she frequently shopped at the pharmacy for OTC solutions to address unidentified pain and other ailments related to an unknown disease.

Once diagnosed with an autoimmune disease, prevention became a regular part of Lisa’s day. To minimize exposure to germs and viruses and thereby prevent illnesses, Lisa turned to the pharmacy for products including vitamins, over-the-counter pre-cold remedies, and hand sanitizers. In addition, as a mother, Lisa often shopped for health remedies and other products for her husband and children.

Patients gather information from various touchpoints and needs continue to evolve as a condition unfolds and treatments are prescribed. The pharmacy is a prime touchpoint because it’s a venue patients visit when they’re open to, and often seeking, health-related solutions and education.

At the beginning of the treatment continuum for a chronic disease such as RA, a patient may be most interested in the potential side effects of a particular therapy, whereas over time, concerns shift to more global issues including affordability and adherence.

Even now, Lisa seeks solutions for occasional health needs both related and unrelated to her main diagnosis. Though Lisa’s medication is filled through a specialty pharmacy and shipped to her home, she turns to retail and community pharmacies on a regular basis for a variety of needs.

Weaving the Pharmacy into a DTC Campaign

When handed a new diagnosis, and prescribed a new medication – whether traditional or specialty – patients often hunger for information, feedback, and guidance. Though each individual patient will seek information in different ways, knowledge is often gathered from multiple sources.

So how can the patient perspective help shape a DTC campaign? Listening to the patient experience can help brand marketers identify lingering needs and information gaps. In Lisa’s case, being prescribed a biologic nearly two decades ago left a lot of unanswered questions. She was starved for more information about RA but also how the biologic worked, how it would improve her symptoms, and what she could do to maximize its effect.

Though Lisa feels more medically savvy now out of necessity, at the time she would have liked access to educational content with patient-friendly language. To her, the pharmacy is well suited to disseminate simple messages about particular diseases and conditions.

When Lisa enters a pharmacy, she has health on her mind and she knows the onsite pharmacist is available to address questions and concerns. She finds the setting professional, comforting, and accessible for health-related messaging. In fact, if the option presented itself, she’d jump at the chance to pick up her specialty medication in the neighborhood pharmacy rather than receiving a shipment in her home.

Visiting the pharmacy is not a one-time event. Patients have different needs at each point along the way, affected by medication, age, and a variety of other factors. Patients with chronic diseases often continue to cope with a few minor symptoms, particularly at the beginning of a new treatment option. Therefore, the pharmacy can be a vehicle for driving patients to other resources such as a comprehensive disease website or online tools to help manage the disease burden.

Build Customer Awareness at the Pharmacy Level

With shrinking budgets and increased scrutiny of traditional DTC advertising, marketing tactics need to be more targeted, more effective, and less expensive. Specialty pharma marketers in particular are tasked with learning about the people taking their products, and that includes uncovering their needs. Who can clearly define patient needs and wants better than the patient himself?

Listening to patients can help marketers identify the best messaging approach before creating a branded shelf aid in the pharmacy or creating a magazine advertisement. Targeted products for specific populations, like RA for example, require a targeted marketing plan even though the number of patients affected by the disease is large. In some cases, the patient pool prescribed specialty medications is quite small which requires a more focused messaging approach.

Patients rely on specialty pharmacies to dispense specialty medications; however, the same patients are also regularly stopping by retail pharmacies. In fact, these patients may spend even more time in drugstore aisles than the average consumer. It’s a moment in time when the patients have their own health concerns – and likely that of a child, parent, or spouse as well – top of mind.

The pharmacy is an appropriate setting to deliver strong messages to patients while they’re looking to improve their health. Drugstore aisles are a proven platform to reach patients with targeted and specific information that helps establish a close link and provide the support needed. In-store campaigns can also open the door to other media channels, driving the patient to continue the brand experience. Integrated programs that include multiple touchpoints such as mobile and internet reinforce messaging found in store aisles.

The Next Powerful Patient Story Awaits

Marketers hope the messages they develop motivate patients to take action. Some patients may respond positively to information about how a newly marketed product differs from those that have been available for years. Another patient type may want to be informed in order to open a conversation with a pharmacist or physician. The communication’s value and credibility increases exponentially by having a healthcare professional available in-store. Patients can easily discuss questions and concerns with a pharmacist and in some cases, a nurse practitioner or physician assistant.

We’ve all heard of the cardiologist who has an epiphany about what a patient truly needs once he himself has had to endure triple bypass surgery. When patients share real-life experiences of their diagnoses, it’s the closet way to feel their pain and see their struggle without actually having the disease ourselves. Keeping real-life patient stories in mind can elevate a marketing campaign’s effectiveness and ensure the product and patient develop a genuine and worthy connection.

 

 

 

Kathleen Bonetti


February 23, 2017 0

movember foundationOn February 17th, the Movember Foundation went beyond the moustache by expanding their promotional efforts through PatientPoint. With prostate cancer now the second most common form of cancer seen in men in the U.S., the two organizations teamed up to spread awareness and inspire healthy action between men and their healthcare professionals. According to Paul Villanti, the executive director of the Movember Foundation, “too many men don’t talk about their health, don’t take action, and as a result, they die too young from diseases that are often treatable”. PatientPoint programs impact half a billion patient and caregiver visits each year –this kind of reach will be huge for Movember Foundation and help them push towards their goal: to stop men dying too young.

To learn more about Movember, click here, or to read the news release, click here.

Lily Stauffer


January 16, 2017 0

Pharmaceutical patient apps are a hot topic among brand teams these days. They hold great promise for a brand across the patient journey, from supporting a dialog with physicians to setting treatment expectations to supporting disease or lifestyle management to providing support to maximize adherence.

Yet, for all its promise, many brand teams have been disappointed with the results of their patient apps, measured in terms of downloads (scale), repeat usage (engagement) and business impact. I’ve witnessed a number of factors that drive this. Among them:

  • Failing to identify a user real need
  • Failing to differentiate from competitive apps
  • Insufficient focus on recruitment
  • Failing to integrate the app into a wider patient support ecosystem
  • Failing to maintain the app

These are fundamentally product design and management challenges and they usually result from a failure to plan adequately in advance.

If you are thinking about an app for your band, first remember this: 80-90% of apps are used once and then deleted, according to a study by Compuware. Then answer these seven deceptively simple questions. It can mean the difference between success and failure.514136851

  1. Who are the patient needs we are trying to serve?

Sadly, most pharma apps exist to serve a business purpose. If you are planning an app, make sure you have defined a clear and pressing user need. Market research is a must and ethnography is a great tool to help you discover real pain points in a patient’s experience and in their use of your product.

  1. How will we differentiate?

In the app universe, pharma not only competes against other drug manufacturers but also digital health start-ups and publishers. If the need you seek to fill is already being satisfied, think twice about duplicating it, unless you have a clear plan to provide a significant leap in utility.

  1. Do we understand the drivers of utility?

Most successful apps do a small number of things exceptionally well. Involve patients in the design process to understand which features will give you the biggest bang for the buck. Avoid feature creep.

  1. Do we understand how the app links to our wider support ecosystem?

The best apps out there are a single node of a broader digital ecosystem. All of the pieces fit together. For example, the app is linked to the nurse call center, which is linked to the patient support site. You will avoid the “silo” trap if you set out to design an integrated patient experience, not an app.

  1. How will we drive enrollment?

A scan through pharma app download statistics will reveal a sad truth: most are only seen by a very small percentage of patient populations. To avoid this fate, you need a clear plan to drive recruitment. There are many options here ranging from search, to social network ads, to rep-pull through.

  1. Should we build or partner/buy?

Pharma companies are great at partnering when it comes to licensing medicines, but for some reason when it comes to apps, the tendency is to build versus partner. As a result, a lot of money is wasted creating functionality that already exists or could be built faster, cheaper, and better with a start-up or health publishing partner. Smart Patient and Mango Health are two examples of companies partnering well with pharma.

  1. How do we create a bridge to business value?

The best apps put the user first and provide a compelling, easy-to-use differentiated experience. But they also have a commercial strategy. Whatever your app’s purpose, think creatively about how to drive the behavioral result you desire.  Define this “conversion event” and built it into the user experience.

Happy apping!

 

Republished with permission. Click here to read the original posting on MediaPost.

Gregg Fisher


January 14, 2017 0

Over the past 25 years, PatientPoint has established themselves as a leader of patient and physician engagement solutions at the point of care. The company closed out 2016 on a high, with the launch of a new mobile app, PatientPoint 360, as well as the acquisition of MedCenterDisplay. This week, they kept the momentum rolling with the announcement of their new collaboration with the American Heart Association. With a network of over 290,000 healthcare providers, PatientPoint will be able to share the AHA’s public service announcements and educational content on a large scale, further extending the mission to build heart-healthier lives. Senior Vice President of content and creative for PatientPoint, Katie Merz, says that “the collaboration will provide patients in our growing cardiology networkaha access to a powerful resource to help them find the tips, tools—and therapies—to better care for their heart”.

To learn more, visit www.patientpoint.com

Lily Stauffer


November 15, 2016 0

Appealing to millennials is difficult enough for most industries, however the health insurance industry specifically struggles, as millennials feel invincible, and would rather diagnose themselves through Web MD than visit the doctor. Steve McCallion, CMO and creative director at Zoom+, recognizes this, and has developed a new approach to targeting millennials. McCallion says, “millennials are a healthy group, so you have to figure out how they think of their healthcare on a deeper level…not just something they have to do, but they want to do”. The team at Zoom+ emphasizes the millennial love for wellness, by offering incentives for healthy lifestyles, such as running a marathon. They know this younger age group is much more concerned with eating healthy and staying active than seeking medical intervention. One of their first campaigns was an animation, reminiscent of Schoolhouse Rock! The idea was to take the lengthy and confusing language of the ACA, and put it into a platform that millennials can relate to and understand.

To learn more about how Zoom+ is engaging millennials from MM&A, click here.

Lily Stauffer


November 8, 2016 0

For those below the poverty line, the elderly and the disabled, often their ability to visit the doctor depends heavily on available transportation. A 2005 study revealed that an estimated 3.6 million people do not receive nonemergency care for this reason. Uber, the leading ride-sharing technology company recognized this problem, and collaborated with Circulation, a technology company to launch a pilot program aimed decreasing the frequency these demographics miss doctor’s appointments. The program will be launching at Boston Children’s Hospital, the Mercy Health System in Philadelphia, and the Nemours Children’s Health System in Delaware. When asked his thoughts on the program, Chief Innovation Officer at Boston Children’s Hospital, John Brownstein stated, “A no-show? That’s a cost to the system. There’s [also] a downstream impact on the patients”.

To read more about Uber’s pilot program from MM&M, click here.

 

Lily Stauffer


November 1, 2016 0

A few years back, Remedy Health Media launched a set of stories meant to help bring patients’ stories to life, following their “Live Bold, Live Now” platform. Today, the company pulled inspiration from the widespread popularity of “Humans of New York”, by launching two new initiatives looking to foster personal engagements with patients.

Their new goal is to reach patients who want snippets of personal stories, those that either already have a large knowledgebase of their condition, or those who are not willing to commit the time to watching long videos and blogs. Jim Curtis, president of advertising at Remedy, notes that “we’re looking at Instagram and other publishers that are really able to tell a story in a moment”.

To learn more about Remedy’s two new initiatives from MM&M, click here.

Lily Stauffer


November 1, 2016 0

Pharma marketers and advertisers are posed daily with the challenge of portraying information about conditions that people do not talk about publically. In an attempt to unveil such conditions, Takeda launched “IBD Unmasked”, a global campaign aiming to raise awareness of IBD, a condition that affects five million people globally. The company are the first in the pharmaceutical space to partner with Marvel Custom Solutions, having super heroes portray patients suffering from IBD.

The campaign was launched initially in July, however the first chapter of the comic book became available last week at London’s Comic Con. One of the primary characters in the book, Samarium, is a young US research scientist who suffers from ulcerative colitis, but possesses super strength, speed and agility.samarium

Head of global product and pipeline communication, Elissa Johnsen was quoted saying “At Takeda we believe that IBD Unmasked will continue to celebrate the strength that real life IBD superheroes exhibit every day and go on to spark powerful conversations, transform perceptions, and ultimately improve understanding of the impact of these diseases”.

To read more about this creative campaign from MM&M, click here.

Lily Stauffer


October 13, 2016 0

Contrary to popular belief that soaring drug prices translates to growing wealth for manufacturers, the royalties within the insulin market are going directly to the middlemen. Also known as pharmacy-benefit managers (PBMs), their purpose in the market is to negotiate rebates and fees based on list prices. In light of the recent price increase of Mylan’s EpiPen, angry consumers are voicing their opinions about the high list prices of everyday drugs.

Since 2011, there have been significant insulin price increases from big manufacturers such as Sanofi, Eli Lilly and Novo Nordisk. Harvard professor Aaron Kesselheim suggests that this can in part be attributed to the growing number of patients under high-deductible plans, shifting the cost from the insurer to the consumer.

However, the revenue acquired by the drug maker after discounts has stayed the same, or in some cases even fallen. Reason being, pharmaceutical companies compete to remain on the preferred drug list by offering deeper and deeper discounts. In exchange for their spot on the list, PBMs demand higher rebates, making it difficult for companies to turn a growing profit.

Steve Miller, CMO of Express Scripts, the largest PBM in the U.S., acknowledges that “certain patients get caught in the middle of this, and we have got to figure out how to put guard rails around that,” such as setting a maximum pharmacy price”.

To read more about insulin pricing and reimbursement from the Wall Street Journal, click here.

 

Lily Stauffer


September 23, 2016 0

The worst part of the Zika story we know so far, is that we do not know nearly enough to combat it in a meaningful way. First it was just an exotic STD from South America. Then it turns out to be a virus that could cause severe disability in newborns. As of August 2016, the CDC has reported that there are 2,722 Zika cases across the United States, another 14,110 in the US Territories (not counting the sexually transmitted cases), active mosquito-borne transmission in every country from Mexico, south through the Caribbean and Central America, to Ecuador, Colombia and Brazil in South America.  New studies indicate the virus is associated with brain disorders in adults, for example Guillain-Barré syndrome.  According to Florida State University researchers, the Zika virus directly targets the development of brain cells, in as little as three days after exposure, effectively stunting the cells' growth.

The United Nations Health Agency noted in its new warning on the virus that “the more we know, the worse things look,” while World Health Organization’s Director-General Dr. Margaret Chan said that in under a year, the status of Zika has changed from ‘a mild medical curiosity’ to a disease with severe public health implications. Meanwhile, the CDC reported just a few days ago that they are almost out of money to fight this growing epidemic, which is unfortunate for many states and Puerto Rico which heavily rely on Federal help.

We still do not know what type of global impact on the spread of Zika the past Olympic games will play, but with the fast approaching annual rainy season in South America we are in for a perfect storm of factors that could become the tipping point to spreading the virus globally, unless concrete steps are taken now.

Clinical trials to make vaccines are still in process, and won’t progress anytime soon for that matter, if the stock market is any indicator.  Companies like Sanofi (NYSE:SNY), Inovio Pharmaceuticals (NASDAQ:INO), Intrexon Corp (NYSE:XON), and others have announced Zika vaccines initiatives, but the investors are clearly not impressed.

That leaves us with the next most logical option: detection.  Making easy to use, rapid, reliable, and cost-effective testing tools widely available across the affected region will help slow the spread and is a key preventative measure for this global epidemic.

Dr. Yelena Budovskaya, Ph. D., whose company Xnsion is at the cutting edge of rapid testing development, explains the difficulty labs face when tackling the problem with traditional methods. According to Dr. Budovskaya, “Most new technologies target the development of an instrument or adapting already existing instruments to allow rapid detection of one or few potential causes of infection. These instruments are expensive and would require significant investments for a diagnostic lab to adapt and adopt these instruments for the detection of various disease and infections; and in this case – Zika. Combined with the high cost of tests and limited testing availabilities, very limited information is available about the epidemiology of Zika: from its geographic origin, patterns, down to the possibility of health impacts and studies regarding Zika co-infections with other mosquito- or tick-borne viruses. The other fundamental problem with current Zika testing technologies is that they heavily rely on antibodies against the Zika virus. However, the Zika virus is very similar to other mosquito-borne viruses which makes those test unspecific. “

Yet, while, companies like Xnsion do appear to have the answer, it has yet to reach the market. The stalemate seems to be in the partnership that should have been a fertile ground for growth and innovation: between the public and the private sectors. One is in the business of advancement of public health, while the other is in the business of offering effective solutions for a profit. Inertia of one, causes inertia in the other, and rightfully so.

Big corporations do exist for the ultimate goal of enriching their shareholders, and they simply cannot afford to invest into solutions that will not have the backing of the public sector. Right now the “best” (CDC recommended) test costs ~$20-25 per sample that makes it out of reach in many struggling economies, which also happens to be the countries most affected by the virus at the moment.

Public health experts say that a viable test should utilize standard molecular laboratory equipment, be simple enough to be performed by any laboratory technician without necessity for in-depth knowledge in molecular biology, and should cost below $10 per test.

I believe we could get there, and the price will be driven down by normative market laws of supply and demand through increased competition if the private sector sees a serious commitment from the Federal government here at home, the World Health Organization, and of course local governments across the region.

Combating the Zika virus falls out of the normative boundaries of global responsibility. It is not about more affluent countries providing aid to developing nations. The threat to global health is real, and is a joint responsibility of the leading nations and each individual government in the affected region to step up to the plate. One cannot expect the private sector to go at it alone, although one can expect them to deliver, if the other side does their job, as opposed to the ongoing jockeying currently happening in the US Congress, such as blocking President Obama’s request for the necessary funds.

It is easy to call out the pharma industry for being the bad guys. But maybe, now is the perfect opportunity for the public sector to show them what good guys look like, and help create the market conditions for an affordable, accurate, scalable, adaptable and, most importantly, rapid Zika diagnostics.

Givi Topchishvili